Gender Differences Are a Leading Factor in 5-Year Survival of Patients with Idiopathic Pulmonary Fibrosis over Antifibrotic Therapy Reduction

Gender Differences Are a Leading Factor in 5-Year Survival of Patients with Idiopathic Pulmonary Fibrosis over Antifibrotic Therapy Reduction

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease with a median survival of 3–5 years. Antifibrotic therapies like pirfenidone and nintedanib slow progression, but the outcomes vary. Gender may influence disease presentation, progression, and response to treatmen...

Full description

Saved in:
Bibliographic Details
Main Authors: Pasquale Tondo, Giulia Scioscia, Cosimo C. De Pace, Fabiola Murgolo, Federica Maci, Giulia M. Stella, Dalila Pescatore, Maria Pia Foschino Barbaro, Donato Lacedonia
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Life
Subjects:
IPF
survival
nintendanib
pirfenidone
antifibrotic treatment
Online Access:https://www.mdpi.com/2075-1729/15/1/106
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2075-1729/15/1/106

Similar Items